Ghrelin receptor agonist hexarelin attenuates analgesic tolerance to morphine in rats
Background
Opioids like morphine are powerful analgesics, but their long-term use is hampered by the development of analgesic tolerance, requiring escalating doses and increasing side effects. Ghrelin, a peptide hormone primarily known for stimulating growth hormone release and appetite, also exhibits analgesic properties via the growth hormone secretagogue receptor (GHS-R). However, the interaction between ghrelin system agonists and opioid analgesia, particularly in the context of tolerance, has not been fully elucidated. This study investigates whether activating the GHS-R with a synthetic agonist could modulate morphine's effectiveness and mitigate the development of tolerance, potentially offering a novel strategy to improve long-term pain management.
Study Design
The study used a total of 104 Wistar albino male adult rats. To induce morphine tolerance, a three-day cumulative dose regimen was employed. On day 4, rats were assessed for tolerance. The analgesic effects of hexarelin (0.2 mg·kg-1), the GHS-R antagonist [d-Lys3]-GHRP-6 (10 mg·kg-1), and morphine (5 mg·kg-1) were measured. Pain response was evaluated at 30-minute intervals (0, 30, 60, 90, and 120 min) using the tail-flick and hot-plate analgesia tests.
Results
The co-administration of the ghrelin receptor agonist hexarelin with morphine significantly enhanced morphine's antinociceptive (pain-reducing) effect. Furthermore, this combination attenuated the development of analgesic tolerance to morphine. In contrast, the ghrelin receptor antagonist, [d-Lys3]-GHRP-6, did not produce any significant analgesic activity or effect on morphine tolerance when tested in the analgesia assays. The findings consistently showed that activating the GHS-R alongside morphine administration leads to a more potent and sustained analgesic response while counteracting the tolerance that typically develops with repeated opioid use.
The data indicate that administration of GHS-R agonist hexarelin with morphine enhances the antinociception and attenuates morphine tolerance.
Key Findings
- Co-administration of hexarelin and morphine enhances the analgesic effect of morphine.
- Hexarelin, when given with morphine, attenuates the development of analgesic tolerance.
- The ghrelin receptor antagonist [d-Lys3]-GHRP-6 had no significant effect on morphine tolerance.
- Analgesic effects were measured at 30, 60, 90, and 120 minutes using tail-flick and hot-plate tests.
Why It Matters
The results suggest a potential clinical application for GHS-R agonists like hexarelin as adjuncts to opioid therapy. By co-administering hexarelin with morphine, it may be possible to use lower doses of opioids, achieve better pain control, and delay or prevent the onset of tolerance, a major barrier in chronic pain management. This could reduce the risk of dose escalation and associated side effects. While this is an early-stage animal study, it points toward a novel pharmacological strategy for improving the safety and efficacy of long-term opioid treatment. Further research is needed to confirm these effects in humans and to establish optimal dosing protocols for combination therapy.
